role of alpha one(a1)adrenoceptor antagonist in benign prostatic hyperplasia in diabetic patients

Summary and Conclusion : Both Benign prostatic hyperplasia (BPH) and Diabetes mellitus are common men of the same age group and a possible association may important merapeutically. In our study, the efficacy of selective 0.1 antagonist; Terazosin; in the treatment of micturational disorders associated with diabetes, was conducted in I prospective controlled study. Evaluation was primarily based on IPSS, uroflowmetry and residual urine. Treatment with Terazosin led to marked improvement in the subjective lPSS) and objective (Q-max and post void residual urine) parameters in both aiabetic and non diabetic patients with BPH. In comparison between the two groups; the pretreatment values have a sgnificant difference in the IPSS and Q-max, but not in PVR; while in the post treatment values; the significant difference was in the IPSS and PVR, but not in Q·max. : There are no significant changes in prostate size, PSA and symptoms score ineach group and in comparison to each other. The adverse events occurred due to administration of Terazosin were generally mild. In conclusion, diabetes is associated with greater BPH symptom severity. Treatment with 0.1 antagonist (Terazosin) appears to reduce lower urinary tract symptoms similarly in patients with BPH with or without diabetes. Terazosin, is safe, effective and will tolerated by the patients, moreover, its additional effect on blood pressure is a great advantage for patients with hypertension as a concomitant disease 95.